- Home
- Latest news
Latest news
What you need to know about Johnson & Johnson’s 2024 fourth-quarter and full-year earnings report
Check out this infographic breakdown of the company’s fourth-quarter and full-year performance, with highlights from its Innovative Medicine and MedTech businesses.
Inside Johnson & Johnson’s decades-long quest to develop effective IBD treatments
Inflammatory bowel disease doesn’t have a cure—yet. But the recent FDA approval of a promising medication is the latest in a long line of treatments from Johnson & Johnson that are helping patients with IBD.
More from Johnson & Johnson
The future of immunology
Learn about the advances Johnson & Johnson is making to potentially help treat the millions of people living with conditions in which the immune system mistakenly damages healthy cells in the body.
Johnson & Johnson named a 2025 Fortune World’s Most Admired Company
A dedication to innovation and social responsibility are just two of the qualities that helped the company garner a coveted spot on the list for the 23rd year in a row.
Careers
Looking for a career opportunity at Johnson & Johnson? Search our available jobs.
5 things we now know about eczema
The most common inflammatory skin disease causes scaly patches, blisters and severe itching, but it’s far more than just a cosmetic concern. Learn why Johnson & Johnson is focused on helping the millions living with this painful condition.
What is metastatic cancer?
The number of people living with this advanced form of cancer is on the rise. Learn how Johnson & Johnson is pioneering innovations to help patients live longer.
“The surgical devices I design help speed healing and save lives”
Candice Otrembiak’s work combines her love of science with her natural problem-solving skills. The result: high-tech devices that help make medical procedures more efficient for surgeons and safer for patients.
Using your own cells to fight cancer
Cell therapy is bringing the world one step closer to eliminating cancer. Here’s how Johnson & Johnson is moving this cutting-edge therapy forward.
Press releases
Johnson & Johnson MedTech Announces Clearance of MONARCHTM QUEST for Enhanced Robotic-Assisted Bronchoscopy
Next-generation NVIDIA-powered AI navigation software elevates MONARCHTM Platform for Robotically Assisted Bronchoscopy
Johnson & Johnson MedTech Showcases New Era of Digital Orthopaedics at AAOS 2025
Building on last year’s momentum of 18 FDA 510(k) Clearances and 45 global product launches, the company accelerates innovation across joint reconstruction, trauma, spine, and more
Icotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patients
Topline results also show investigational targeted oral peptide icotrokinra achieved clinical remission rates up to 30.2% at Week 12 and a favorable safety profile in Phase 2b ANTHEM-UC study Clinical response and remission rates continued to improve through Week 28, building on strong data recently reported for the plaque psoriasis Phase 3 program Icotrokinra demonstrates potential to offer therapeutic benefit and tolerability with a once daily oral treatment
Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis
Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigm Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with investigational icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD Topline results from Phase 3 ICONIC-ADVANCE 1&2 studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe plaque PsO These results pave the way to initiate the first-ever head-to-head study seeking to demonstrate the superiority of a pill versus injectable biologic in moderate-to-severe plaque PsO
